Subscribe to RSS
DOI: 10.1055/a-2523-5684
Lower Extremity Vein Thrombosis And Recurrence in Patients with Behcetʼs Syndrome: How And When?
Venen thrombose der unteren Extremitäten und Rezidiv bei Patienten mit Morbus Behçet: Wie und wann?
Abstract
Objective
We aimed to investigate the risk and time to recurrence of venous thrombosis (VT) in patients with BS, focusing on clinical features and laboratory parameters.
Method
A total of 67 BS patients with (n=32) and without (n=35) venous thrombosis (VT) fulfilled the diagnostic criteria of the International Criteria for Behcet’s Disease (ICBD) and were included in the study. Clinical features (onset of BS-related symptoms, presence of VT relapse and cutaneous ulcer, and the results of vascular system imaging), demographical data, duration of symptoms, time to diagnosis, delayed time to diagnosis, and patient follow-up periods were retrospectively obtained from medical records. Disease activity was assessed using the Behcet’s Disease Current Activity Form (BDCAF).
Results
VT was statistically more common in the male population. In the VT group, superficial thrombophlebitis (STF) was more frequent, while papulopustular lesions (PPL) and arthritis were also observed more often compared to the non-VT group. Median time to VT onset was 2 years (minimum: 0–27). The first episode of VT occurred within the first 5 years of disease onset in 68.75% (n=22/32) of patients. VT recurrence occurred in 21.8% of patients (n=7/32). The time to VT recurrence was a median of 3 years (min, max, 3–5 years) following the first VT episode. There was a statistically significant correlation between post-thrombotic cutaneous ulcers (PTCUs) and a positive pathergy test (p=0.048). Time to VT onset was 2.23 years in smokers and 6.38 years in non-smokers. This difference was found to be statistically significant when evaluated by a log-rank test (p=0.05).
Conclusion
VT develops earlier in BS patients who smoke and have a family history of BS. One of the unique findings of our study is that pathergy test positivity predicts the risk of developing PTCUs. Although VT is most common within the first 5 years of the BS, VT recurrence occurs within the first 10 years.
Publication History
Article published online:
27 February 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Yazici H, Seyahi E, Hatemi G. et al. Behçet syndrome: a contemporary view. Nature Reviews Rheumatology 2018; 14: 107-119
- 2 Davatchi F, Shahram F, Chams-Davatchi C. et al. Behcet’s disease: from east to west. Clinical Rheumatology 2010; 29: 823-833
- 3 Mahr A, Maldini C. Epidemiology of Behçet’s disease. La Revue de medecine interne 2014; 35: 81-89
- 4 Cakir N, Dervis E, Benian O. et al. Prevalence of Behçetʼs disease in rural western Turkey: a preliminary report. Clin Exp Rheumatol 2004; 22: S53-S55. https://pubmed-ncbi-nlm-nih-gov.accesdistant.sorbonne-universite.fr/15515786/
- 5 Gürler A, Boyvat A, Türsen U. Clinical manifestations of BehÇet’s disease: an analysis of 2147 patients. Yonsei Medical Journal 1997; 38: 423-423
- 6 Tascilar K, Melikoglu M, Ugurlu S. et al. Vascular involvement in Behcetʼs syndrome: a retrospective analysis of associations and the time course. Rheumatology 2014; 53: 2018-2022
- 7 Alibaz-Oner F, Karadeniz A, Yılmaz S. et al. Behçet Disease With Vascular Involvement. Medicine 2015; 94: e494-e494
- 8 Sarr S, Fall P, Mboup M. et al. Superior vena cava syndrome revealing a Behçet’s disease. Thrombosis Journal 2015; 13: 7
- 9 Hatemi G, Christensen R, Bang D. et al 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Annals of the Rheumatic Diseases Published online April 6 2018; annrheumdis-2018-213225
- 10 Kural-Seyahi E, Fresko I, Seyahi N. et al. The Long-Term Mortality and Morbidity of Behçet Syndrome. Medicine 2003; 82: 60-76
- 11 Ozguler Y, Hatemi G, Cetinkaya F. et al. Clinical course of acute deep vein thrombosis of the legs in Behçet’s syndrome. Rheumatology 2019; 59: 799-806
- 12 Kaban N, Harman H. The effectiveness of adalimumab as an add-on therapy in two cases with leg ulcers in Behçet’s disease resistant to conventional immunosuppressive therapy alone and a review of the literature. Modern Rheumatology Case Reports 2023; 8: 205-209
- 13 Alibaz-Oner F, Vautier M, Aksoy A. et al Vascular Behçet’s disease: a comparative study from Turkey and France. Clinical and Experimental Rheumatology Published online 2021;
- 14 Girgin S, Yurumez S, Omma A. et al. Comparison of relapse rates in Behçet’s disease with venous involvement on different doses of azathioprine therapy, a retrospective observational study. International Journal of Rheumatic Diseases 2021; 24: 562-566
- 15 Davatchi F, Assaad-Khalil S, Calamia KT. et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology 2013; 28: 338-347
- 16 Cheon JH, Kim ES, Shin SJ. et al. Development and Validation of Novel Diagnostic Criteria for Intestinal Behçet’s Disease in Korean Patients With Ileocolonic Ulcers. The American Journal of Gastroenterology 2009; 104: 2492-2499
- 17 Watanabe K, Tanida S, Inoue N. et al. Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. Journal of Gastroenterology 2020; 55: 679-700
- 18 Lawton G, Bhakta BB, Chamberlain MA. et al. The Behçet’s disease activity index. Rheumatology (Oxford) 2004; 43: 73-78
- 19 Tabachnick BG, Fidell LS. Using Multivariate Statistics. 6th ed. Boston Pearson; 2013
- 20 Davatchi F, Chams-Davatchi C, Shams H. et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Review of Clinical Immunology 2017; 13: 57-65
- 21 Rodríguez-Carballeira M, Solans R, Larrañaga JR. et al. Venous thrombosis and relapses in patients with Behçet’s disease. Descriptive analysis from Spanish network of Behçet’s disease (REGEB cohort). Clinical and Experimental Rheumatology 2018; 36: 40-44. https://pubmed-ncbi-nlm-nih-gov.accesdistant.sorbonne-universite.fr/29745871/
- 22 Houman MH, Ben Ghorbel I, Khiari Ben Salah I. et al. Deep vein thrombosis in Behçet’s disease. Clinical and Experimental Rheumatology 2001; 19: S48-S50. https://pubmed-ncbi-nlm-nih-gov.accesdistant.sorbonne-universite.fr/11760399/
- 23 Erden F, Karagoz H, Avci A. et al. The values of mean platelet volume and the mean platelet volume/platelet ratio for predicting deep venous thrombosis in Behçet’s disease. LaboratoriumsMedizin 2017; 41
- 24 Seyahi E. Phenotypes in Behçet’s syndrome. Internal and Emergency Medicine 2019; 14: 677-689
- 25 Kalay Yıldızhan İ, Boyvat A. Diagnostic Sensitivity of Different Applications of Pathergy Test for Behçet’s Disease. Archives of Rheumatology 2020; 35: 29-34
- 26 Melikoglu M, Ugurlu S, Tascilar K. et al Large vessel involvement in Behçet’s syndrome: a retrospective survey. Ann Rheum Dis 2008; 67: 67
- 27 Ko GY, Byun JY, Choi BG. et al. The vascular manifestations of Behçet’s disease: angiographic and CT findings. The British Journal of Radiology 2000; 73: 1270-1274
- 28 Koç Y, Güllü I, Akpek G. et al. Vascular involvement in Behçet’s disease. The. Journal of Rheumatology 1992; 19: 402-410. https://pubmed-ncbi-nlm-nih-gov.accesdistant.sorbonne-universite.fr/1578454/
- 29 Sarica-Kucukoglu R, Akdag-Kose A, Kayabalı M. et al. Vascular involvement in Behcet’s disease: a retrospective analysis of 2319 cases. International Journal of Dermatology 2006; 45: 919-921
- 30 Emmi G, Bettiol A, Silvestri E. et al. Vascular Behçet’s syndrome: an update. Internal and Emergency Medicine 2018; 14: 645-652
- 31 Desbois AC, Wechsler B, Resche-Rigon M. et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. 2012; 64: 2753-2760
- 32 Hatemi G, Seyahi E, Fresko I. et al Behçet’s syndrome: one year in review 2022. Clinical and Experimental Rheumatology Published online 2022;